Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.
Study Type
OBSERVATIONAL
Enrollment
10,328
Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
Seoul National University Hospital
Seoul, South Korea
Locoregional recurrence-free survival (LRR)
Time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of locoregional recurrence
Time frame: Defined as the time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of LRR, assessed up to 120 months
Distant metastasis-free survival
Time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of distant metastasis
Time frame: Defined as the time interval between the date of initial administration of chemotherapy and date of pathological or radiological confirmation of distant metastasis, assessed up to 120 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.